Form 4: Galectin CFO Sells Shares Under 10b5-1 Plan

Galectin Therapeutics' Chief Financial Officer, Jack W. Callicutt, executed a pre-planned sale of 8,706 common shares following the exercise of stock options.

Summary

• Jack W. Callicutt, Chief Financial Officer of Galectin Therapeutics Inc. (GALT), reported transactions on September 12, 2025.
• He exercised 8,706 stock options at an exercise price of $1.37 per share.
• Concurrently, he sold 8,706 shares of common stock at a weighted average price of $6.4385 per share, with individual sale prices ranging from $6.33 to $6.68.
• These transactions were conducted under a Rule 10b5-1 plan adopted on April 17, 2025, and previously disclosed in the Issuer's Quarterly Report on Form 10-Q filed on August 14, 2025.
• Following these transactions, Callicutt's direct beneficial ownership of common stock is 7,614 shares, and his beneficial ownership of derivative securities (options) is 0.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider sale under a 10b5-1 plan. While insider selling can sometimes be viewed negatively, the pre-planned nature mitigates immediate concerns. The officer realized a significant profit, which is positive for the individual but neutral to slightly negative for the company's stock perception.

Positives

• The officer realized a significant profit from exercising options at $1.37 and selling shares at a weighted average of $6.4385.
• The transaction was pre-planned under a Rule 10b5-1 plan, indicating a structured approach to equity monetization rather than an immediate reaction to market conditions.

Negatives

• The sale of shares by a Chief Financial Officer could be perceived by some investors as a reduction in direct insider ownership, potentially signaling a minor decrease in alignment with shareholder interests.

Risks

• No specific new risks for the company are mentioned in this Form 4 filing. The primary risk is market perception of insider selling, even if pre-planned.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns. The reduction in direct insider ownership could be seen as a minor decrease in alignment.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

The filing details a pre-planned insider sale by the CFO, which is a routine event under a Rule 10b5-1 plan. While the sale itself reduces insider ownership, the pre-scheduled nature suggests it is not a reaction to new negative information. The significant profit realized by the CFO from the option exercise is positive for the individual but does not provide a strong signal for the company's future performance. Without additional company-specific news or financial updates, this Form 4 alone does not warrant a change from a 'hold' position.

Keywords

Galectin Therapeutics, GALT, Jack W. Callicutt, CFO, Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Beneficial Ownership